Angelo Carpi – författare

The current age of clinical medicine is witnessing biotechnological innovation at an unprecedented pace. As a result, the recently popularized clinical practice guidelines (CPG), as a tool to assist clinical decision-making, have been struggling to keep up. Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines rides the wave of medical innovation, analyzing current and future CPG, and providing an up-to-date and comprehensive treatise on thyroid cancer, its diagnosis, and treatment.A synthesis of ideas by prominent world experts in the field of thyroid cancer research and clinical practice, Thyroid Cancer coversTechnologically-advanced diagnostic procedures and therapeutic interventions Diagnostic techniques employed in the detection and follow-up of thyroid cancer including ultrasound, needle aspiration techniques, CT, PET, PET-CT, and MRIBasic principles of systems biology, molecular and translational medicine, CPG development, and risk stratification for thyroid cancerHow CPG contain knowledge gaps and produce uncertaintyAdvances in the field, including new surgical techniques, molecular targeted therapies, external beam radiation therapy, and chemotherapyA comprehensive, scientific description of current and future diagnostic and therapeutic modalities for the management of thyroid cancer, this treatise is an indispensible reference for both the specialist and referring physician. Support materials can be downloaded and are available at www.routledge.com/9781439862216

The current age of clinical medicine is witnessing biotechnological innovation at an unprecedented pace. As a result, the recently popularized clinical practice guidelines (CPG), as a tool to assist clinical decision-making, have been struggling to keep up. Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines rides the wave o

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer m

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single VolumeThe book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer DiagnosisPresents noninvasive early molecular markers in urological cancersDescribes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myelomaProvides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanomaThis text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.

The current age of clinical medicine is witnessing biotechnological innovation at an unprecedented pace. As a result, the recently popularized clinical practice guidelines (CPG), as a tool to assist clinical decision-making, have been struggling to keep up. Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines rides the wave of medical innovation, analyzing current and future CPG, and providing an up-to-date and comprehensive treatise on thyroid cancer, its diagnosis, and treatment.A synthesis of ideas by prominent world experts in the field of thyroid cancer research and clinical practice, Thyroid Cancer coversTechnologically-advanced diagnostic procedures and therapeutic interventions Diagnostic techniques employed in the detection and follow-up of thyroid cancer including ultrasound, needle aspiration techniques, CT, PET, PET-CT, and MRIBasic principles of systems biology, molecular and translational medicine, CPG development, and risk stratification for thyroid cancerHow CPG contain knowledge gaps and produce uncertaintyAdvances in the field, including new surgical techniques, molecular targeted therapies, external beam radiation therapy, and chemotherapyA comprehensive, scientific description of current and future diagnostic and therapeutic modalities for the management of thyroid cancer, this treatise is an indispensible reference for both the specialist and referring physician. Support materials can be downloaded and are available at www.routledge.com/9781439862216

The current age of clinical medicine is witnessing biotechnological innovation at an unprecedented pace. As a result, the recently popularized clinical practice guidelines (CPG), as a tool to assist clinical decision-making, have been struggling to keep up. Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines rides the wave o

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single VolumeThe book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer DiagnosisPresents noninvasive early molecular markers in urological cancersDescribes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myelomaProvides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanomaThis text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.